Uploaded December 2025 | Updated November 2026, 1 day ago
Presented By: Chris Long, PhD
Speaker Biography: Christopher Long is the Director of Engineering and Automation at Hesperos, Inc., a growth-stage start up focusing on microphysiological systems (MPS devices), in vitro-based devices recapitulating physiological conditions for disease modeling, drug discovery, and personalized medicine. Dr. Long earned his Ph.D. in Materials Science and Engineering from the University of Florida, and has been developing MPS devices since 2010. As a member of Hesperos since the company first spun out of the University of Central Florida in 2015, Dr. Long has overseen the engineering development, pharmacokinetic-pharmacodynamic modeling, and integration of Hesperos’ Human-on-a-Chip® MPS platform, which focuses on measuring functional changes in organ constructs in multi-organ devices with a common recirculating medium. Multi-organ Human-on-a-Chip systems enable interactions among the different organ modules, which are especially important when effects due to compound metabolism, disease-related mutations, or soluble factor production are not previously well established. Dr. Long developed pharmacokinetic modeling algorithms for application to specialized multi-organ microfluidic devices for predicting time-dependent drug and metabolite concentrations. The models are not only informative, but also drive the development of the structure of the microfluidic network to optimize concentration profiles.
Webinar: Human-on-a-Chip for Translational PK/PD and Disease Modeling: Cardiac Ischemia, a Patient-Specific Model for CMT2S, and the First Digital Twin Informed by an Organ-on-a-Chip System
Webinar Abstract: Animal models often fall short of predicting human outcomes, creating costly translational failures. Human-on-a-Chip systems address this by reproducing key aspects of human physiology to generate clinically relevant insights into the safety and efficacy of therapeutics. Combined with quantitative PK/PD modeling, these platforms deliver human-relevant preclinical insights and enable research into rare diseases where models are limited or non-existent. This talk covers three applications:
First, a cardiac ischemia model that imposes controlled hypoxia and reperfusion within a multi-organ context. Contractile force, electrophysiology, and injury biomarkers quantify damage and recovery enabling evaluation of candidate therapeutics.
Second, a patient-specific neuromuscular junction (NMJ) model for Charcot-Marie-Tooth type 2S. Using iPSC-derived motoneurons and skeletal muscle from the patient alongside healthy controls, we recapitulated NMJ dysfunction and quantified rescue by the client’s therapeutic, as measured by functional readouts. This N-of-1 study supported the FDA’s decision to grant Orphan Drug Designation of a sponsor’s therapeutic illustrating how these platforms can guide therapies for diverse genetic disorders.
Third, we extend our multi-organ PK/PD capabilities to the first published Digital Twin informed by an organ-on-a-chip system, in which longitudinal biological data informed in silico models to predict response and improve translatability.
Together, these studies show how integrated human biology and quantitative modeling can reduce reliance on animal studies, de-risk development, and shorten the path from preclinical insight to clinical decisions.
Learning Objectives:
1. Describe the principles of multi-organ Human-on-a-Chip systems, and list which clinically relevant readouts are used to model cardiac ischemia and recovery.
2. Describe how a Human-on-a-Chip informed Digital Twin is established and explain its potential to improve drug development.
3. Evaluate the integration of organ-on-a-chip data with quantitative PK/PD modeling and digital twin approaches to improve clinical translatability.
Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (labroots.com/virtual-event/cell-bio-2025) 2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/virtual-event/cell-bio-2025/agenda) 3. Click Here to get your PACE credits (Expiration date – 9/17/2026): (labroots.com/virtual-event/cell-bio-2025/continuing-education-credits) This link will be located in the CMS in the webinar CE tab – please enable third party PACE link
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc
Presented By: Chris Long, PhD
Speaker Biography: Christopher Long is the Director of Engineering and Automation at Hesperos, Inc., a growth-stage start up focusing on microphysiological systems (MPS devices), in vitro-based devices recapitulating physiological conditions for disease modeling, drug discovery, and personalized medicine. Dr. Long earned his Ph.D. in Materials Science and Engineering from the University of Florida, and has been developing MPS devices since 2010. As a member of Hesperos since the company first spun out of the University of Central Florida in 2015, Dr. Long has overseen the engineering development, pharmacokinetic-pharmacodynamic modeling, and integration of Hesperos’ Human-on-a-Chip® MPS platform, which focuses on measuring functional changes in organ constructs in multi-organ devices with a common recirculating medium. Multi-organ Human-on-a-Chip systems enable interactions among the different organ modules, which are especially important when effects due to compound metabolism, disease-related mutations, or soluble factor production are not previously well established. Dr. Long developed pharmacokinetic modeling algorithms for application to specialized multi-organ microfluidic devices for predicting time-dependent drug and metabolite concentrations. The models are not only informative, but also drive the development of the structure of the microfluidic network to optimize concentration profiles.
Webinar: Human-on-a-Chip for Translational PK/PD and Disease Modeling: Cardiac Ischemia, a Patient-Specific Model for CMT2S, and the First Digital Twin Informed by an Organ-on-a-Chip System
Webinar Abstract: Animal models often fall short of predicting human outcomes, creating costly translational failures. Human-on-a-Chip systems address this by reproducing key aspects of human physiology to generate clinically relevant insights into the safety and efficacy of therapeutics. Combined with quantitative PK/PD modeling, these platforms deliver human-relevant preclinical insights and enable research into rare diseases where models are limited or non-existent. This talk covers three applications:
First, a cardiac ischemia model that imposes controlled hypoxia and reperfusion within a multi-organ context. Contractile force, electrophysiology, and injury biomarkers quantify damage and recovery enabling evaluation of candidate therapeutics.
Second, a patient-specific neuromuscular junction (NMJ) model for Charcot-Marie-Tooth type 2S. Using iPSC-derived motoneurons and skeletal muscle from the patient alongside healthy controls, we recapitulated NMJ dysfunction and quantified rescue by the client’s therapeutic, as measured by functional readouts. This N-of-1 study supported the FDA’s decision to grant Orphan Drug Designation of a sponsor’s therapeutic illustrating how these platforms can guide therapies for diverse genetic disorders.
Third, we extend our multi-organ PK/PD capabilities to the first published Digital Twin informed by an organ-on-a-chip system, in which longitudinal biological data informed in silico models to predict response and improve translatability.
Together, these studies show how integrated human biology and quantitative modeling can reduce reliance on animal studies, de-risk development, and shorten the path from preclinical insight to clinical decisions.
Learning Objectives:
1. Describe the principles of multi-organ Human-on-a-Chip systems, and list which clinically relevant readouts are used to model cardiac ischemia and recovery.
2. Describe how a Human-on-a-Chip informed Digital Twin is established and explain its potential to improve drug development.
3. Evaluate the integration of organ-on-a-chip data with quantitative PK/PD modeling and digital twin approaches to improve clinical translatability.
Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (labroots.com/virtual-event/cell-bio-2025) 2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/virtual-event/cell-bio-2025/agenda) 3. Click Here to get your PACE credits (Expiration date – 9/17/2026): (labroots.com/virtual-event/cell-bio-2025/continuing-education-credits) This link will be located in the CMS in the webinar CE tab – please enable third party PACE link
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc










